Novartis AG's chances of eventually dominating the multibillion dollar multiple-sclerosis market with its new Gilenya pill got a boost Wednesday when Merck KGaA of Germany abandoned attempts to market a rival treatment.
Merck's decision to stop market applications for its MS medicine cladribine and pull the product from Russia and Australia—which comes after the U.S. Food and Drug Administration required more testing to allay safety concerns—means Novartis has the only oral multiple-sclerosis treatment in the market at the moment. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309